Redirecting to https://markets.businessinsider.com/news/stocks/arrivent-announces-first-patient-dosed-in-global-pivotal-phase-3-alpacca-trial-evaluating-firmonertinib-for-first-line-treatment-of-egfr-pacc-mutant-non-small-cell-lung-cancer-1035664265